Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 448 participants.

Also called NCT01224366

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 448 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01224366
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Belgium, Czechia, Germany, Guatemala, Hong Kong SAR China, Hungary, India, Romania, Slovakia, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01224366. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Vildagliptin
Intervention (Drug)
Placebo
Lead sponsor
Novartis (class: industry)

Record details

Record id
cardio:ct-nct01224366
Content hash
080c491cdd22f91978ba67c37d9459db7cb0624ecb06fb553ab722b459a1c529